-- UBSは、アリツィア（ATZ.TO）が5月7日に発表する第4四半期決算で堅調な業績を報告し、1株当たり利益が予想を0.08ドル上回ると予測している。 アナリストは、アリツィア株の買い推奨と目標株価168.00ドルを維持しており、同社が第4四半期も力強い成長を維持し、第1四半期の業績見通しも好調に推移すると予想している。 「こうした勢いにもかかわらず、アリツィアは2027年度の業績見通しについて保守的なアプローチを取り、5年間のアルゴリズムに基づき売上高成長率を15～17%と見込んでいる。市場はこの動向を認識しており、この慎重な姿勢が投資家の長期的なファンダメンタルズ分析に影響を与えるとは考えにくい。」 UBSは、アリツィア株が短期から中期的に市場平均を上回るパフォーマンスを示すと予想している。
Price: $143.29, Change: $+2.06, Percent Change: +1.46%
Oneview Healthcare (ASX:ONE) reported cash receipts from customers of about 3.3 million euros for the first quarter, compared with 4.2 million euros a year earlier, according to a Monday filing with the Australian bourse.The company noted that the year-ago figure includes two large customer receipts totaling more than 2 million euros, which were due to be received during the fourth quarter of 2024 but were received in early 2025.Oneview Healthcare ended March with a cash balance of AU$17.1 million, up from AU$8.1 million at the close of 2025, per the filing.The company's shares gained 3% in recent Monday trade.
Paradigm Biopharmaceuticals (ASX:PAR) is set to progress participants through the day 112 follow-up period for the phase three trial evaluating injectable pentosan polysulfate sodium for the treatment of pain associated with knee osteoarthritis in the June quarter, which is required for inclusion in the interim analysis dataset, according to a Monday Australian bourse filing.The independent statistical analysis results for the data set are expected around August. Timing remains subject to the scheduling and review processes of independent third parties, and there is a reasonable likelihood that final interim outcomes may extend into September, it cautioned.The interim analysis is expected to provide the first phase three evaluation of efficacy and safety for injectable pentosan polysulfate sodium in knee osteoarthritis. Primary endpoint top-line results are expected in the March 2027 quarter.Its shares fell 14% in recent trading on Monday, reaching their lowest point in over a year.
Sanan Optoelectronics (SHA:600703) posted first-quarter attributable net profit of 67.5 million yuan, down 68% from 211.9 million yuan the previous year.Earnings per share declined to 0.01 yuan from 0.04 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue declined 33% year over year to 2.91 billion yuan from 4.31 billion yuan.Shares of the software company declined 2% in recent trade.